Phaseline

Targets › AKT1

AKT1 (RAC-alpha serine/threonine-protein kinase): drug programs, companies and trials

11 programs from 10 companies in 56 trials: 24 Phase 2, 20 Phase 1, 12 Phase 3; Oncology, Other, Gastroenterology; next expected readout Nov 2026.

AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. (UniProt, P31749)

Open in Phaseline: the race on AKT1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstraZenecaCapivasertib
Serine/threonine-protein kinase AKT inhibitor
AKT2, AKT3, AKT1Phase 3Locally Advanced (Inoperable) or Metastatic Breast Cancer; Prostate Cancer; Triple Negative Breast Neoplasms; Breast Cancer …Nov 2026
LaeknaAfuresertib
Serine/threonine-protein kinase AKT inhibitor
AKT2, AKT3, AKT1Phase 3Breast CancerDec 2026
RocheIpatasertib
Serine/threonine-protein kinase AKT inhibitor
AKT2, AKT3, AKT1Phase 3Cancer; Ovarian Cancer; Solid Tumors; Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer …Feb 2028
Zhejiang Haichang BiotechWGI-0301
Antisense oligonucleotide complementary to Akt-1 mRNA
AKT1Phase 2Advanced Hepatocellular Carcinoma (HCC)Dec 2026
National Cancer Institute (NCI)Uprosertib
Serine/threonine-protein kinase AKT inhibitor
AKT2, AKT3, AKT1Phase 2Recurrent Uveal MelanomaJul 2027
VA Office of Research and DevelopmentItraconazole
Cytochrome P450 51 inhibitor
SMO, AKT1, VEGFAPhase 2Esophageal AdenocarcinomaApr 2029
Merck & Co. (MSD)Miransertib (MK-7075)
Serine/threonine-protein kinase AKT inhibitor
AKT2, AKT3, AKT1Phase 2PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS); Proteus SyndromeFeb 2030
QuantumLeap Healthcare CollaborativeMK-2206
Serine/threonine-protein kinase AKT inhibitor
AKT2, AKT3, AKT1Phase 2Breast NeoplasmsDec 2030
Alterome TherapeuticsALTA2618
AKT1 E17K inhibitor
AKT1Phase 1CancerDec 2026
National Cancer Institute (NCI)Mk-2206 (MK2206)
Serine/threonine-protein kinase AKT inhibitor
AKT2, AKT3, AKT1Phase 1Advanced Malignant Solid NeoplasmMar 2027
Atavistik BioATV-1601
AKT1 E17K inhibitor
AKT1Phase 1Hereditary Hemorrhagic Telangiectasia (HHT); Advanced Solid TumorsDec 2027

Conditions

Breast Cancer (5) Metastatic Breast Cancer (4) Advanced Lymphoma (3) Locally Advanced (Inoperable) or Metastatic Breast Cancer (2) Prostate Cancer (2) Triple Negative Breast Neoplasms (2) Cancer (2) Hormone-Sensitive Prostate Cancer (1) Locally Advanced or Metastatic Breast Cancer (1) Moderate Hepatic Impairment (1) Metastatic Castration-resistant Prostate Cancer (mCRPC) (1) CCCA Assessed by Ki67 Drop Below <2.7% From Baseline (1)

Modalities

small molecule (7), mixed (4)

Companies

National Cancer Institute (NCI) (2) AstraZeneca (1) Merck & Co. (MSD) (1) Roche (1) Laekna (1) Alterome Therapeutics (1) QuantumLeap Healthcare Collaborative (1) Zhejiang Haichang Biotech (1) Atavistik Bio (1) VA Office of Research and Development (1)

Related targets

AKT2 (7) AKT3 (7) SMO (1) VEGFA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.